|
The Body Covers: The 8th Conference on Retroviruses and Opportunistic Infections
Antiretroviral Chemotherapeutic Agents: Preclinical Studies
February 6, 2001 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
In this laboratory study, MPA was used at a range of doses (0-500 nM) which represent achievable serum concentrations. In combination with these NRTIs, both wild-type and resistant clones were inhibited in a dose-proportional manner. The use of MPA together with ddI and ABC demonstrated synergy. Neither the NRTIs nor MPA had an adverse effect on cell proliferation. These data suggest that MPA may be a useful adjunct to therapy with ddI, abacavir and tenofovir at doses of MPA that do not induce immunosuppression, and is worthy of further clinical testing. A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.
|